Analyst ratings can significantly influence investor perception and stock prices. A downgrade from 'Outperform' to 'Market Perform' suggests that the analyst sees fewer growth catalysts or higher risks ahead for CymaBay Therapeutics, which could lead to a negative short-term impact on the stock price.